Prologis CEO Dan Letter joins Bloomberg Businessweek Daily to discuss the state of global logistics and shipping as geopolitics and associated risk impacts the firm's customer base. However, Prologis is optimistic about its data center business. Letter says the company's strong relationship with hyperscalers is ongoing, bolstering "a fortress of a balance sheet" as Prologis continues to secure lon...
Prologis CEO Dan Letter joins Bloomberg Businessweek Daily to discuss the state of global logistics and shipping as geopolitics and associated risk impacts the firm's customer base. However, Prologis is optimistic about its data center business. Letter says the company's strong relationship with hyperscalers is ongoing, bolstering "a fortress of a balance sheet" as Prologis continues to secure longer-term power capacity. Letter speaks with Carol Massar and Tim Stenovec. (Source: Bloomberg)
Earnings Call Insights: Tivic Health Systems, Inc. (TIVC) Q4 2025 Management View Michael Handley, CEO, announced, "It is a privilege to address you for the first time as CEO of Tivic. I'm honored to lead the company at this transformative juncture. My focus is clear and resolute evolving Tivic into a high-impact immunotherapy company dedicated to saving lives, advancing critical therapies to pati...
Earnings Call Insights: Tivic Health Systems, Inc. (TIVC) Q4 2025 Management View Michael Handley, CEO, announced, "It is a privilege to address you for the first time as CEO of Tivic. I'm honored to lead the company at this transformative juncture. My focus is clear and resolute evolving Tivic into a high-impact immunotherapy company dedicated to saving lives, advancing critical therapies to patients and delivering significant long-term value to our shareholders." Handley highlighted the company’s full pivot into immunotherapy, now anchored by the TLR5 platform, with lead candidates Entolimod and Entolasta at the center of this new strategic direction. Handley stated the company completed its acquisition of in-house manufacturing capabilities and launched Velocity Bioworks, which is expected to offer both cost efficiencies for Tivic and a new revenue stream as a contract manufacturing organization. "By internalizing our manufacturing, we have already achieved substantial reduction in development time lines and costs for Entolimod. Additionally, we have controlled our own supply chain and are poised to scale Entolimod as needed." The CEO described the discontinuation of all non-core businesses, including the ClearUP device and neuromodulation programs, allowing Tivic to focus exclusively on biotherapeutics: "By shedding these legacy assets, we have concentrated 100% of our resources on high-value biotherapeutic opportunities." Handley outlined a strategic focus on the oncology supportive care market, referencing its estimated value of nearly $15 billion and expected growth to $20 billion by the 2030s. He emphasized that Tivic is "aggressively moving Entolimod into large market clinical indications, beginning with neutropenia," and targeting physician-sponsored trials within the year. The CEO also pointed to active engagement with U.S. government agencies for potential biodefense contracts: "We are actively engaged with BARDA, NIAID and the Department of Water to sec...
Rybakina completes 2-6, 6-3, 6-4 comeback win American slumps to fifth straight defeat to Kazakhstani Jessica Pegula had her chances. Midway through the second set of yet another enormous match with Elena Rybakina, the American had engineered a flawless start. After bulldozing through the opening set, Pegula’s level at the beginning of set two put her in with a fair shot of snatching a win against...
Rybakina completes 2-6, 6-3, 6-4 comeback win American slumps to fifth straight defeat to Kazakhstani Jessica Pegula had her chances. Midway through the second set of yet another enormous match with Elena Rybakina, the American had engineered a flawless start. After bulldozing through the opening set, Pegula’s level at the beginning of set two put her in with a fair shot of snatching a win against her Kazakhstani opponent, who has dominated their recent meetings. Instead, Pegula departed Miami with another tough lesson to parse through after being shown once again that the best players in the world pounce on even the smallest drops in intensity. Despite her mediocre start, Rybakina produced a brilliant comeback to reach the Miami Open semi-finals with a 2-6, 6-3, 6-4 win. Continue reading...
Constellation Energy (NASDAQ: CEG) provided a nice jolt to investors' portfolios in mid-week trading. On news that an influential investment bank resumed coverage of the stock with a bullish update on Wednesday, investors snapped up the shares, sending them up 3% that trading session. The person behind this was Morgan Stanley 's David Arcaro, who flagged Constellation stock as an overweight (read:...
Constellation Energy (NASDAQ: CEG) provided a nice jolt to investors' portfolios in mid-week trading. On news that an influential investment bank resumed coverage of the stock with a bullish update on Wednesday, investors snapped up the shares, sending them up 3% that trading session. The person behind this was Morgan Stanley 's David Arcaro, who flagged Constellation stock as an overweight (read: buy) at a $385 price target. That's 27% above its latest closing price. Image source: Getty Images. Continue reading
Sturm, Ruger & Company ( RGR ) said on Wednesday its board has received a letter from Beretta Holding S.A. proposing a partial tender offer for up to 20.05% of its outstanding shares. The company said the proposed offer, which has not yet commenced, could raise Beretta’s ownership stake in Ruger to about 30% if completed. Ruger said its board will review the proposal with advisers and respond in d...
Sturm, Ruger & Company ( RGR ) said on Wednesday its board has received a letter from Beretta Holding S.A. proposing a partial tender offer for up to 20.05% of its outstanding shares. The company said the proposed offer, which has not yet commenced, could raise Beretta’s ownership stake in Ruger to about 30% if completed. Ruger said its board will review the proposal with advisers and respond in due course, adding that shareholders do not need to take any action at this time. Source: Press Release More on Sturm, Ruger Sturm, Ruger & Company: New Platforms And Entry Into The Accessory Business Sturm, Ruger & Company, Inc. (RGR) Q4 2025 Earnings Call Transcript Sturm, Ruger & Company: 'In And Out' Is One Way To Play This One In 2026 Beretta offers to boost its stake in Sturm, Ruger by another 20% with a tender offer Firearms face-off: Sturm, Ruger and Beretta scrap over board seats
Most good investments start when the crowd is moving in the opposite direction of what you are buying. Right now, it feels like Wall Street is punishing anything with "AI" in the pitch deck, rotating out of tech into energy and consumer staples, and convincing itself the party is over. I'll be honest. I don't mind seeing this artificial intelligence (AI) pullback . I've been saying for a while tha...
Most good investments start when the crowd is moving in the opposite direction of what you are buying. Right now, it feels like Wall Street is punishing anything with "AI" in the pitch deck, rotating out of tech into energy and consumer staples, and convincing itself the party is over. I'll be honest. I don't mind seeing this artificial intelligence (AI) pullback . I've been saying for a while that AI stock valuations have gotten ahead of themselves. To be clear, that doesn't mean AI isn't real or durable -- it absolutely is -- but the level of hype, aggressive funding rounds, and stretched multiples was getting a bit excessive. That said, being skeptical of all the hype doesn't mean value isn't present. As capital rotates and sentiment cools, opportunities start to show up in places the market isn't paying attention to. Continue reading
narong sutinkham/iStock via Getty Images Introduction The Canadian company Poet Technologies Inc. ( POET ) is in the midst of the transition from a pre-revenue stage to operational expansion and commercialization of its photonic integrated circuits (PICs) and optical modules (800G and 1.6T, with the 3.2T in the development stage), protected by patents. As I explained, its main innovation is the Op...
narong sutinkham/iStock via Getty Images Introduction The Canadian company Poet Technologies Inc. ( POET ) is in the midst of the transition from a pre-revenue stage to operational expansion and commercialization of its photonic integrated circuits (PICs) and optical modules (800G and 1.6T, with the 3.2T in the development stage), protected by patents. As I explained, its main innovation is the Optical Interposer , which integrates photonic and electronic components on a single chip without wires. The advantages of this solution are lower cost (fewer components are needed) and power efficiency. We immediately understand that we are talking about the intriguing layer of the AI stack. Compute is where NVIDIA and AMD play, while we find POET in the infrastructure and networking layers. This means that POET is not a computer or a software company. Its optical engines move data between AI accelerators at extremely fast speeds (basically, the speed of light). Without this role, GPUs would be a massive bottleneck for AI. With an analogy taken from the human body, NVIDIA plays the role of the brain, while POET produces components that are part of the nervous system. After developing the technology, POET has secured manufacturing capacity through Globetronics and NationGate in Malaysia. The company also has a partnership with Mitsubishi, Foxconn, and Luxshare, which are suppliers of the hyperscalers. It may sound obvious, but if POET manages to execute, it could be a real beneficiary of the ongoing data center buildout, which is expected to last, at least, through 2030. As POET shows, the inflection point for 800G demand is already behind us, but 2026 is the ramp year for 1.6T, which should soon see its TAM grow to $1.5B in two years, with the $15B landmark in sight by 2030 . To sum it all up, the TAM that POET estimated in its investor presentation has already been revised by 43% for 2026 and by 46% for 2027 . POET Investor Presentation A big variable for POET is CPO (co-pa...
Never miss an episode. Follow The Big Take daily podcast today. Two decades ago, a federal prosecutor in Florida spent two years investigating Jeffrey Epstein and urged her superiors to charge him. Her frustrations mounted as her boss, US Attorney Alex Acosta, pursued a now-infamous plea deal that allowed Epstein to serve just 13 months, much of it on work release. On today’s Big Take podcast, Blo...
Never miss an episode. Follow The Big Take daily podcast today. Two decades ago, a federal prosecutor in Florida spent two years investigating Jeffrey Epstein and urged her superiors to charge him. Her frustrations mounted as her boss, US Attorney Alex Acosta, pursued a now-infamous plea deal that allowed Epstein to serve just 13 months, much of it on work release. On today’s Big Take podcast, Bloomberg legal reporter David Voreacos joins host Sarah Holder to examine emails and evidence recently released by the Justice Department. They reveal Marie Villafaña’s exhaustive efforts to hold Epstein accountable — and how, despite years of credible evidence, he managed to slip through the cracks. Read more: Sex-Crimes Prosecutor's Repeated Pleas for Epstein's Arrest Were Denied Listen and follow The Big Take on Apple Podcasts , Spotify or wherever you get your podcasts. Terminal clients: click here to subscribe. This episode was produced by: Julia Press; Editors: Jeffrey Grocott; Fact-checker: Eleanor Harrison-Dengate and David Fox; Sound Design/Engineer: Katie McMurran; Senior Producer: Naomi Shavin; Senior Editor: Elisabeth Ponsot; Deputy Executive Producer: Julia Weaver; Executive Producer: Nicole Beemsterboer.